<DOC>
	<DOCNO>NCT00043082</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know carboplatin effective without liposomal doxorubicin treat recurrent ovarian epithelial primary peritoneal cancer . PURPOSE : Randomized phase III trial determine effectiveness carboplatin without liposomal doxorubicin treat patient recurrent ovarian epithelial primary peritoneal cancer .</brief_summary>
	<brief_title>S0200 Carboplatin With Without Doxil Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient platinum-sensitive recurrent ovarian epithelial primary peritoneal cancer treat carboplatin without pegylated doxorubicin HCl liposome . - Compare progression-free survival , confirm complete response rate , time treatment failure patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease measurability ( elevate CA 125 v nonmeasurable disease without elevate CA 125 v measurable disease ) , number disease site ( 2 few v 3 ) , serous tumor histology ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive carboplatin IV 15 minute pegylated doxorubicin HCl liposome IV 1 hour day 1 . - Arm II : Patients receive carboplatin IV arm I . Treatment arm repeat every 4 week total 15 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 6 month 3 year , annually 7 year . PROJECTED ACCRUAL : A total 900 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial carcinoma Stage III IV disease time initial stag laparotomy Primary peritoneal mixed Mullerian tumor allow No borderline ovarian tumor Disease progression recurrence progressionfree platinumfree interval 624 month completion firstline platinumbased chemotherapy ( either single agent combination therapy ) Disease progression recurrence base solely CA 125 elevation allow , provide one follow true : Prior baseline CA 125 great 35 U/mL subsequent normalization great 35 U/mL must CA 125 great 2 time upper limit normal ( ULN ) 2 occasion least 1 week apart Prior baseline CA 125 great 35 U/mL never normalize must CA 125 great 2 time nadir value 2 occasion least 1 week apart Prior normal baseline CA 125 ( great 35 U/mL ) must show CA 125 great 2 time ULN 2 occasion least 1 week apart No known brain metastasis PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic SGOT and/or SGPT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Bilirubin great ULN Renal Creatinine great 1.9 mg/dL Cardiovascular No New York Heart Association class IIIV cardiac disease No clinical evidence congestive heart failure Ejection fraction great 50 % MUGA 2dimensional echocardiogram Other Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , incidental carcinoid cancer No evidence active uncontrolled infection No severe gastrointestinal symptom ( i.e. , partial obstruction ) and/or gastrointestinal bleed diarrhea No great grade 1 preexist sensory neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy At least 28 day since prior biologic consolidation therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 28 day since prior nonplatinumcontaining consolidation chemotherapy No prior pegylated doxorubicin HCl liposome No prior cumulative anthracycline ( e.g. , doxorubicin , daunorubicin , epirubicin ) dose excess 240 mg/m^2 No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy Radiotherapy No prior abdominopelvic irradiation No concurrent radiotherapy Surgery See Disease Characteristics At least 28 day since prior surgical debulking disease progression recurrence recover No concurrent surgery Other No prior treatment 624 month progressionfree platinumfree interval except 12 course consolidation therapy No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>